ACTHAR
What it found
The trial ended early for another reason (see below).
Reason given: Terminated early due to lack of resources.
What was tested
Treatment tested
- Corticotropin
Melanocortin receptor 2 agonist
Safety
| Group | Participants at risk | Serious adverse events | Deaths |
|---|---|---|---|
| Treated Group | 0 | 0 | 0 |
As posted on ClinicalTrials.gov. Serious adverse events include any serious health event during the trial, whether or not the treatment caused it.
What it measured
Main measures
Change in T1 Lesion Relaxation Time
12 month after the completion of intervention
MRI lesions
Other measures (1)
Change in Immune Subset Expression in CD4+FOXP3 Tregs by Flow Cytometry Post ACTHAR Intervention
6 month after the completion of intervention
RelapsesImmune response
Who could take part
MS (type not specified) · 18 and over
Inclusion Criteria: * age > 18 * undergoing a clinical relapse and associated MRI active lesion Exclusion Criteria: * Recent infection, any * use of any glucocorticoid 30 days prior to enrollment * unable to consent
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
ACTHAR is a FDA approved drug for MS relapses. The purpose of the study is to examine the efficacy of this agent in improving relapses as measured by advanced MRI and laboratory techniques: 1. Advanced serial MRI studies on patients during and after an acute MS relapse. MRI will be performed at baseline, 1 month after the 1st dose of ACTHAR, and months 3, 6, and 12. ACTHAR will be administered for 10 days. Patients will start ACTHAR within 48 hours of relapse assessment. 2. Serial immune assays on patients during and after an acute MS relapse. Serum and blood samples with be collected at baseline, last day of ACTHAR (day 10 of therapy), 1 month post 1st dose, and months 3 and 6.
Loading reviews and guidelines…
Related trials
- MS-Children
Status unknown
Result in a paper, not read yet
- Effect of Corticosteroids on Inflammation at the Edge of …
Phase 2 · Recruiting
Still running
- Evaluation of the Response to Acthar Gel Therapy in Patie…
Not a drug-phase study · Status unknown
No result found
- ACTHAR
Phase 4 · Stopped early
Stopped early
- GSK239512 DDI Study
Phase 1 · Completed
No result found
- Pulse ACTH vs. MP for MS
Phase 1 · Completed
No result found
History
Started
Dec 2016
Main results due
Oct 2020
Finished
Oct 2020
Results posted
May 2024
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error